We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $392M
1-Year Est. Return 31.85%
This Fund
S&P 500
This Quarter Est. Return
+6.2%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$308M
AUM Growth
+$9.21M
Cap. Flow
+$6.33M
Cap. Flow %
2.05%
Top 10 Hldgs %
96.57%
Holding
15
New
2
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
SNOW icon
Snowflake
SNOW
+$11M
2
NRIX icon
Nurix Therapeutics
NRIX
+$4.53M
3
PDD icon
Pinduoduo
PDD
+$212K
4
VIR icon
Vir Biotechnology
VIR
+$91

Top Sells

Rank Stock Value
1
PMVP icon
PMV Pharmaceuticals
PMVP
+$9.04M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$339K

Sector Composition

Rank Sector Weight
1 Healthcare 94.56%
2 Technology 3.7%
3 Financials 1.33%
4 Consumer Discretionary 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$59.2M
$134M 43.34%
3,908,677
-270,739
-6% -$9.04M
NGM
2
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$29.4M 9.56%
1,493,349
– –
DNLI icon
3
Denali Therapeutics
DNLI
$3.65B
$25.4M 8.24%
323,749
– –
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$23.4M 7.59%
91,975
– –
ALEC icon
5
Alector
ALEC
$168M
$20.4M 6.63%
980,894
– –
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$18.7M 6.08%
554,325
– –
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.15B
$17.6M 5.72%
996,734
– –
FHTX icon
8
Foghorn Therapeutics
FHTX
$266M
$13.5M 4.37%
1,261,261
– –
SNOW icon
9
Snowflake
SNOW
$102B
$11.4M 3.7%
+47,136
New +$11M
FFBC icon
10
First Financial Bancorp
FFBC
$3.55B
$4.1M 1.33%
173,576
– –
NRIX icon
11
Nurix Therapeutics
NRIX
$2.41B
$4.1M 1.33%
+154,426
New +$4.53M
BEAM icon
12
Beam Therapeutics
BEAM
$2.63B
$4.01M 1.3%
31,131
– –
PDD icon
13
Pinduoduo
PDD
$126B
$1.25M 0.4%
9,806
+1,632
+20% +$212K
VIR icon
14
Vir Biotechnology
VIR
$1.46B
$1.22M 0.4%
25,866
+2
+0% +$91
RUBY
15
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-12,791
Closed -$339K

Similar funds

WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
RC
Riposte Capital New York $392M AUM 69.08% 1-Year Est. Return
DCM
Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BWM
Buckley Wealth Management Las Vegas, Nevada $392M AUM 28.21% 1-Year Est. Return
IPW
Inlet Private Wealth Jupiter, Florida $392M AUM 25.74% 1-Year Est. Return
TCM
Turas Capital Management Boston, Massachusetts $392M AUM
MA
Mezzasalma Advisors Tinton Falls, New Jersey $391M AUM 40.85% 1-Year Est. Return

Euclidean Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Euclidean Capital held 15 positions worth $308M, up 3.1% from $299M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Euclidean Capital's Q2 2021 filing shows 2 new, 2 increased, 1 reduced and 1 closed positions. Its largest new stake was Snowflake: 47,136 shares worth $11.4M. The largest sale was PMV Pharmaceuticals, an estimated $9.04M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

  • Euclidean Capital's largest Q2 2021 buy was Snowflake: 47,136 shares worth $11.4M.
  • Euclidean Capital added most to Pinduoduo in Q2 2021, an estimated $212K increase.
  • Euclidean Capital's biggest Q2 2021 reduction was PMV Pharmaceuticals, cutting an estimated $9.04M.
  • Euclidean Capital fully exited Rubius Therapeutics, Inc in Q2 2021, selling an estimated $339K.
  • Euclidean Capital's ten largest holdings make up 97% of its $308M portfolio in Q2 2021.
  • Euclidean Capital opened 2 new positions and closed 1 in Q2 2021.
  • Euclidean Capital's portfolio value rose 3.1% quarter-over-quarter to $308M.

Based on Euclidean Capital's 13F filing for Q2 2021, filed 16 Aug 2021.